{"title":"结直肠癌酶促基因芯片检测试剂盒快速检测基因表达","authors":"Chan-Han Wu , Fu-Yen Chung , Jia-Yuan Chang , Jaw-Yuan Wang","doi":"10.1016/j.gmbhs.2013.05.004","DOIUrl":null,"url":null,"abstract":"<div><p>A weighted enzymatic chip array (WEnCA) can detect the gene expression of circulating tumor cells (CTCs) in the peripheral blood of patients with colorectal cancer (CRC). In this study, we used a reagent kit, the GeneCling CRC Enzymatic Gene Chip Detection Kit, which was specifically developed for the WEnCA operation platform to analyze the expression of 31 CRC-related genes of CTCs in the peripheral blood of 30 CRC patients. We moreover evaluated the expression of the genes by simultaneously using real-time quantitative polymerase chain reaction (RT-QPCR). The results showed the overexpression rate of nine genes—<em>DVL1</em>, <em>ELAVL4</em>, <em>CHRNB1</em>, <em>UBE2C</em>, <em>PSAT1</em>, <em>CEA</em>, <em>PTTG1</em>, <em>KRT19</em>, and <em>hTERT</em>—was greater than 90% in the CRC patients. This is concordant with the results of the original WEnCA operation procedure. Linear regression analysis demonstrated a high correlation (<em>r</em> = 0.901; <em>p</em> < 0.0001) between the experimental data of the detection kit and RT-QPCR. The GeneCling CRC Enzymatic Gene Chip Detection Kit is easy, fast, and convenient to operate for detecting gene expression of CTCs from peripheral blood. However, the correlation between the differential expression and the clinicopathological features of the 31 CRC-related genes needs further investigation to verify the clinical value.</p></div>","PeriodicalId":100178,"journal":{"name":"Biomarkers and Genomic Medicine","volume":"5 3","pages":"Pages 87-91"},"PeriodicalIF":0.0000,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.gmbhs.2013.05.004","citationCount":"5","resultStr":"{\"title\":\"Rapid detection of gene expression by a colorectal cancer Enzymatic Gene Chip Detection Kit\",\"authors\":\"Chan-Han Wu , Fu-Yen Chung , Jia-Yuan Chang , Jaw-Yuan Wang\",\"doi\":\"10.1016/j.gmbhs.2013.05.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A weighted enzymatic chip array (WEnCA) can detect the gene expression of circulating tumor cells (CTCs) in the peripheral blood of patients with colorectal cancer (CRC). In this study, we used a reagent kit, the GeneCling CRC Enzymatic Gene Chip Detection Kit, which was specifically developed for the WEnCA operation platform to analyze the expression of 31 CRC-related genes of CTCs in the peripheral blood of 30 CRC patients. We moreover evaluated the expression of the genes by simultaneously using real-time quantitative polymerase chain reaction (RT-QPCR). The results showed the overexpression rate of nine genes—<em>DVL1</em>, <em>ELAVL4</em>, <em>CHRNB1</em>, <em>UBE2C</em>, <em>PSAT1</em>, <em>CEA</em>, <em>PTTG1</em>, <em>KRT19</em>, and <em>hTERT</em>—was greater than 90% in the CRC patients. This is concordant with the results of the original WEnCA operation procedure. Linear regression analysis demonstrated a high correlation (<em>r</em> = 0.901; <em>p</em> < 0.0001) between the experimental data of the detection kit and RT-QPCR. The GeneCling CRC Enzymatic Gene Chip Detection Kit is easy, fast, and convenient to operate for detecting gene expression of CTCs from peripheral blood. However, the correlation between the differential expression and the clinicopathological features of the 31 CRC-related genes needs further investigation to verify the clinical value.</p></div>\",\"PeriodicalId\":100178,\"journal\":{\"name\":\"Biomarkers and Genomic Medicine\",\"volume\":\"5 3\",\"pages\":\"Pages 87-91\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.gmbhs.2013.05.004\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers and Genomic Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S221142541300037X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers and Genomic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221142541300037X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rapid detection of gene expression by a colorectal cancer Enzymatic Gene Chip Detection Kit
A weighted enzymatic chip array (WEnCA) can detect the gene expression of circulating tumor cells (CTCs) in the peripheral blood of patients with colorectal cancer (CRC). In this study, we used a reagent kit, the GeneCling CRC Enzymatic Gene Chip Detection Kit, which was specifically developed for the WEnCA operation platform to analyze the expression of 31 CRC-related genes of CTCs in the peripheral blood of 30 CRC patients. We moreover evaluated the expression of the genes by simultaneously using real-time quantitative polymerase chain reaction (RT-QPCR). The results showed the overexpression rate of nine genes—DVL1, ELAVL4, CHRNB1, UBE2C, PSAT1, CEA, PTTG1, KRT19, and hTERT—was greater than 90% in the CRC patients. This is concordant with the results of the original WEnCA operation procedure. Linear regression analysis demonstrated a high correlation (r = 0.901; p < 0.0001) between the experimental data of the detection kit and RT-QPCR. The GeneCling CRC Enzymatic Gene Chip Detection Kit is easy, fast, and convenient to operate for detecting gene expression of CTCs from peripheral blood. However, the correlation between the differential expression and the clinicopathological features of the 31 CRC-related genes needs further investigation to verify the clinical value.